ID: ALA1852155

Max Phase: Preclinical

Molecular Formula: C31H39N3O4S2

Molecular Weight: 581.80

Molecule Type: Small molecule

Representations

Canonical SMILES:  C=C1CN(S(=O)(=O)c2ccc(C)cc2)CCCN(Cc2ccccc2)CCCN(S(=O)(=O)c2ccc(C)cc2)C1

Standard InChI:  InChI=1S/C31H39N3O4S2/c1-26-11-15-30(16-12-26)39(35,36)33-21-7-19-32(25-29-9-5-4-6-10-29)20-8-22-34(24-28(3)23-33)40(37,38)31-17-13-27(2)14-18-31/h4-6,9-18H,3,7-8,19-25H2,1-2H3

Standard InChI Key:  SRJIECKMPIRMJJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 581.80

Molecular Weight (Monoisotopic): 581.2382

AlogP: 4.84

#Rotatable Bonds: 6

Polar Surface Area: 78.00

Molecular Species: NEUTRAL

HBA: 5

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 7

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 7.36

CX LogP: 4.98

CX LogD: 4.70

Aromatic Rings: 3

Heavy Atoms: 40

QED Weighted: 0.39

Np Likeness Score: -0.92

References

1. Chawla R, Van Puyenbroeck V, Pflug NC, Sama A, Ali R, Schols D, Vermeire K, Bell TW..  (2016)  Tuning Side Arm Electronics in Unsymmetrical Cyclotriazadisulfonamide (CADA) Endoplasmic Reticulum (ER) Translocation Inhibitors to Improve their Human Cluster of Differentiation 4 (CD4) Receptor Down-Modulating Potencies.,  59  (6): [PMID:26974263] [10.1021/acs.jmedchem.5b01832]

2. Lumangtad LA, Bell TW..  (2020)  The signal peptide as a new target for drug design.,  30  (10): [PMID:32209293] [10.1016/j.bmcl.2020.127115]

Source

Source(1):

• Scientific Literature